When Accelerated Approval Fails: FDA Withdrawal Trends and Strategic Lessons for Oncology Sponsors
The FDA Accelerated Approval (AA) pathway remains one of the most powerful regulatory mechanisms in oncology, enabling earlier patient access to promising therapies. However, accelerated approval is inherently conditional. When confirmatory trials fail to verify clinical benefit, or are not...
